WO1992019234A3 - Method of treating/preventing substance abuse using 1-alkyl-5(substituted oxy)-2-aminotetralins - Google Patents

Method of treating/preventing substance abuse using 1-alkyl-5(substituted oxy)-2-aminotetralins Download PDF

Info

Publication number
WO1992019234A3
WO1992019234A3 PCT/US1992/002808 US9202808W WO9219234A3 WO 1992019234 A3 WO1992019234 A3 WO 1992019234A3 US 9202808 W US9202808 W US 9202808W WO 9219234 A3 WO9219234 A3 WO 9219234A3
Authority
WO
WIPO (PCT)
Prior art keywords
dependent
substance
individual
treating
preventing
Prior art date
Application number
PCT/US1992/002808
Other languages
French (fr)
Other versions
WO1992019234A2 (en
Inventor
Montford F Piercey
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Priority to JP4511382A priority Critical patent/JPH06506951A/en
Publication of WO1992019234A2 publication Critical patent/WO1992019234A2/en
Publication of WO1992019234A3 publication Critical patent/WO1992019234A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Abstract

Disclosed is a method of caring for human who is or was dependent on a substance which comprises administering to the individual an effective amount of an aminotetralin of formula (I) where caring is (1) treating an individual who is dependent (either physically or psychologically) on a substance, (2) preventing an individual who is recreationally using, but not dependent upon a substance, from becoming dependent on the same or other substances of abuse, (3) preventing an individual who was previously, but not now, dependent from again becoming dependent on a substance, (4) preventing individuals who have no history of substance abuse but from whose life styles and activities clinicians believe are at risk of using substance for recreational purposes and/or becoming dependent on various substances.
PCT/US1992/002808 1991-04-26 1992-04-13 Method of treating/preventing substance abuse using 1-alkyl-5(substituted oxy)-2-aminotetralins WO1992019234A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4511382A JPH06506951A (en) 1991-04-26 1992-04-13 Substance abuse treatment/prevention methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69323891A 1991-04-26 1991-04-26
US693,238 1991-04-26

Publications (2)

Publication Number Publication Date
WO1992019234A2 WO1992019234A2 (en) 1992-11-12
WO1992019234A3 true WO1992019234A3 (en) 1993-01-07

Family

ID=24783880

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/002808 WO1992019234A2 (en) 1991-04-26 1992-04-13 Method of treating/preventing substance abuse using 1-alkyl-5(substituted oxy)-2-aminotetralins

Country Status (5)

Country Link
EP (1) EP0581865A1 (en)
JP (1) JPH06506951A (en)
AU (1) AU1915192A (en)
CA (1) CA2106197A1 (en)
WO (1) WO1992019234A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5554319B2 (en) 2008-04-01 2014-07-23 アボット ゲーエムベーハー ウント カンパニー カーゲー Tetrahydroisoquinolines, pharmaceutical compositions containing them and their use in therapy
AR075442A1 (en) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
TW201319049A (en) 2011-08-05 2013-05-16 Abbott Gmbh & Co Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2780328A1 (en) 2011-11-18 2014-09-24 Abbvie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055770A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
EP3057958B1 (en) 2013-10-17 2019-05-01 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064964A1 (en) * 1981-05-08 1982-11-17 Astra Läkemedel Aktiebolag Therapeutically useful 1-alkyl-2-aminotetralin derivatives
US4800204A (en) * 1987-05-07 1989-01-24 Mueller Peter S Method of controlling tobacco use
US4935429A (en) * 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
US4994486A (en) * 1989-05-31 1991-02-19 Abbott Laboratories Dopaminergic compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064964A1 (en) * 1981-05-08 1982-11-17 Astra Läkemedel Aktiebolag Therapeutically useful 1-alkyl-2-aminotetralin derivatives
US4935429A (en) * 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
US4800204A (en) * 1987-05-07 1989-01-24 Mueller Peter S Method of controlling tobacco use
US4994486A (en) * 1989-05-31 1991-02-19 Abbott Laboratories Dopaminergic compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Alcohol, vol. 7, no. 3, May/June 1990, Pergamon Press plc, (US), G.F. KOOB et al.: "Pharmacology of drug self-administration", pages 193-197, see page 195 *
European Journal of Pharmacology, vol. 182, no. 2, 3 July 1990, Elsevier Science Publishers B.V. (Biomedical Division), M.F. PIERCEY et al.: "Electrophysiological effects of dopamine autoreceptor antagonists, (+)-AJ 76 and (+)-UH 232", pages 219-226, see whole document *
J. Med. Chem., vol. 25, no. 3, 1982, American Chemical Society, D.S. FRIES et al.: "Aminotetralins as narcotic antagonists. 2. Synthesis and opiate-related activity of 1-phenyl-3-aminotetralins", pages 216-220, see whole document *
Journal of Neural Transmission, vol. 65, no. 1, 1986, Springer-Verlag, K. SVENSSON et al.: "(+)-UH 232 and (+)-UH 242: novel stereoselective dopamine receptor antagonists with preferential action on autoreceptors", pages 1-27, see whole document *
Psychopharmacology, vol. 107, no. 1, May 1992, Springer-Verlag, (Berlin, DE), P.M. CALLAHAN et al.: "Effects of the putative dopamine autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 on the discriminative stimulus properties of cocaine", pages 73-77, see whole document *

Also Published As

Publication number Publication date
WO1992019234A2 (en) 1992-11-12
JPH06506951A (en) 1994-08-04
AU1915192A (en) 1992-12-21
CA2106197A1 (en) 1992-10-27
EP0581865A1 (en) 1994-02-09

Similar Documents

Publication Publication Date Title
WO1992019234A3 (en) Method of treating/preventing substance abuse using 1-alkyl-5(substituted oxy)-2-aminotetralins
CA2231803A1 (en) Lipid extract having anti-inflammatory activity
GB9519661D0 (en) Fatty acid treatment
CA2164866A1 (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
AU5227493A (en) Treatment of conditions and disease
OA09736A (en) "Human interleukin-3 and muteins thereof".
WO1992012715A3 (en) The use of loperamide and related compounds for treatment of respiratory disease symptoms
OA09194A (en) "Insecticidal treatment and compositions therefor".
IT1222395B (en) PHARMACEUTICAL COMPOSITION FOR INTRANASAL ADMINISTRATION INCLUDING THE HORMONE GHRH, A COLINERGIC AGONIST AND / OR A BILE SALT
EP0328924A3 (en) Thienotriazolodiazepine compounds and pharmaceutical uses thereof
AU3861989A (en) Method for the treatment and the diagnosis of coronary heart disease
EP0744176A3 (en) Methods for inhibiting bone loss
AU639097B2 (en) Medicament for treating hyperlipidaemia and/or atherosclerosis
AU4006989A (en) Method of inhibiting the spread of disease and infection in structures
EP0354568A3 (en) Novel catechol derivatives
EP0207505A3 (en) Use of a prenyl ketone in the preparation of a medicament against gastritis
EP0273310A3 (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
EP0256942A3 (en) A herbicidal composition
ZA924128B (en) New combination preparations for treatment of Parkinson's disease.
EP0666745A4 (en) Diagnosis and therapy for parkinson's disease.
AU6678194A (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
EP0286802A3 (en) Use of ofloxacin in treating or preventing locally periodontal disease
AU3881889A (en) Human interferon-gamma, process to prepare said human interferon-gamma, and its use
AU1162788A (en) Oxime-ethers of 2,6-dioxobicyclo-(3.3.0)octanones for treatment of heart and circulation diseases
EP0288202A3 (en) Fluoro-sulfones

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992911383

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2106197

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1992911383

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992911383

Country of ref document: EP